Acasti Pharma Inc (ACST)
2.90
-0.03
(-0.97%)
USD |
NASDAQ |
Apr 26, 16:00
2.92
+0.02
(+0.69%)
After-Hours: 20:00
Acasti Pharma Enterprise Value: 2.144M for April 26, 2024
Enterprise Value Chart
Historical Enterprise Value Data
Date | Value |
---|---|
April 26, 2024 | 2.144M |
April 25, 2024 | 2.412M |
April 24, 2024 | 2.144M |
April 23, 2024 | 1.956M |
April 22, 2024 | 1.674M |
April 19, 2024 | 1.862M |
April 18, 2024 | 3.742M |
April 17, 2024 | 4.869M |
April 16, 2024 | 6.374M |
April 15, 2024 | 6.468M |
April 12, 2024 | 6.891M |
April 11, 2024 | 6.844M |
April 10, 2024 | 6.844M |
April 09, 2024 | 6.844M |
April 08, 2024 | 6.844M |
April 05, 2024 | 6.844M |
April 04, 2024 | 6.844M |
April 03, 2024 | 6.656M |
April 02, 2024 | 7.126M |
April 01, 2024 | 7.314M |
March 28, 2024 | 7.079M |
March 27, 2024 | 6.844M |
March 26, 2024 | 6.844M |
March 25, 2024 | 6.938M |
March 22, 2024 | 6.844M |
Date | Value |
---|---|
March 21, 2024 | 6.844M |
March 20, 2024 | 6.844M |
March 19, 2024 | 6.844M |
March 18, 2024 | 6.844M |
March 15, 2024 | 6.656M |
March 14, 2024 | 6.938M |
March 13, 2024 | 6.844M |
March 12, 2024 | 7.126M |
March 11, 2024 | 6.374M |
March 08, 2024 | 6.844M |
March 07, 2024 | 6.844M |
March 06, 2024 | 6.938M |
March 05, 2024 | 6.891M |
March 04, 2024 | 7.220M |
March 01, 2024 | 7.173M |
February 29, 2024 | 6.28M |
February 28, 2024 | 6.844M |
February 27, 2024 | 6.186M |
February 26, 2024 | 6.562M |
February 23, 2024 | 6.374M |
February 22, 2024 | 6.515M |
February 21, 2024 | 6.28M |
February 20, 2024 | 4.118M |
February 16, 2024 | 5.904M |
February 15, 2024 | 3.648M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
-19.60M
Minimum
Dec 12 2022
227.05M
Maximum
Dec 20 2019
33.03M
Average
9.00M
Median
Enterprise Value Benchmarks
Aurinia Pharmaceuticals Inc | 359.58M |
Edesa Biotech Inc | 9.751M |
Lexaria Bioscience Corp | 25.12M |
Xenon Pharmaceuticals Inc | 2.417B |
ESSA Pharma Inc | 126.85M |
Enterprise Value Related Metrics
Net Income (Quarterly) | -2.391M |
Total Expenses (Quarterly) | 3.043M |
EPS Diluted (Quarterly) | -0.0542 |
Earnings Yield | -157.9% |
Normalized Earnings Yield | -171.97 |